"The Post Its Of The Biotech Industry"

Qiagen's products are ubiquitous--and its stock is red-hot

Unlike other biotech pioneers, Qiagen co-founder and Chief Executive Metin Colpan has no aspirations to cure cancer, Alzheimer's disease, or any of the other ills that plague humankind. Not even the common cold is on his radar screen. "You're never going to hear that we are coming out with the next big drug," says Colpan, a 45-year-old biochemist from Qiagen's German headquarters in the town of Hilden, near Dusseldorf.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.